Merit Medical Systems (MMSI)
Makes single-use devices for vascular access, intervention, endoscopy, oncology, and cardiac therapies.
Something off on this page? Send us feedback.
Designs and sells single-use devices for interventional, diagnostic, and therapeutic procedures across cardiovascular and endoscopy markets. Cardiovascular accounts for most sales, spanning vascular access and intervention tools, cardiac and renal therapies, oncology, procedural kits, and OEM supply.
Designs, develops, and manufactures single-use medical devices used in interventional, diagnostic, and therapeutic procedures. Reporting remains split between Cardiovascular and Endoscopy, while the current commercial view groups eight platforms into Foundational and Therapeutic: Access, Cardiac Therapies, Endoscopy, OEM, Oncology, Procedural Solutions, Renal Therapies, and Vascular Intervention.
Builds customer-specific kits, trays, and procedural packs, while the OEM operation supplies components and finished devices to other medical-device manufacturers. Hospitals buy through direct sales teams, distributors, OEM partners, and custom-kit assemblers; clinical education supports adoption.
Sells worldwide and operates manufacturing and packaging sites across North America, Europe, Brazil, and Singapore. Execution depends on product development, regulatory clearance, physician acceptance, reimbursement and pricing pressure, supplier performance, tariffs, and global manufacturing continuity. Each product must be approved under the laws of the country where it is sold.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 31, 2026 | Barrington | Target | Target: $106 | Target: $114 |
| Jul 31, 2026 | Canaccord Genuity | Target | Target: $99 | Target: $94 |
| Jul 31, 2026 | Raymond James | Reiterate | Rating: —Target: $71 | Target: $100 |
| Jul 31, 2026 | BTIG | Reiterate | Rating: —Target: $107 | Target: $105 |
| Jul 31, 2026 | Needham | Reiterate | Rating: —Target: $105 | Target: $101 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $448.7M · Total debt $820.1M · Total assets $2.86B · Shareholders' equity $1.68B
- Revenue
- $418.8M
- Operating income
- $60.5M
- Net income
- $38.8M
No dividends on record.
| Institutions | 106.06% | 63.33M shares | |
|---|---|---|---|
| 410 holders · as of Jun 30, 2026 | |||
| Insiders | 0.80% | 477.4K shares | |
| 18 holders · as of Sep 9, 2026 | |||
| Adds to | 106.86% | ||
59.71M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 106.86%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 15.85% | 9.46M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 5.82% | 3.47M | as of Jun 30, 2026 |
ArrowMark Colorado Holdings, LLCInstitution | 5.21% | 3.11M | filed Feb 14, 2022 |
Vanguard Capital Management LLCInstitution | 4.34% | 2.59M | as of Jun 30, 2026 |
State Street CorpInstitution | 4.14% | 2.47M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 24, 2026 | Neil W. Peterson | officer: CHIEF OPERATING OFFICER | −7,500 | $90.45 |
| Aug 4, 2026 | Neil W. Peterson | officer: CHIEF OPERATING OFFICER | −21,449 | $85.00 |
| May 11, 2026 | Christian Adam Smith | officer: Chief Commercial Officer | +1,626 | $61.00 |
| May 7, 2026 | Brian G. Lloyd | officer: CHIEF LEGAL OFFICER, SECRETARY | +2,000 | $62.63 |
| May 7, 2026 | Lynne N. Ward | director | −5,000 | $62.61 |
- Boston Scientific
Broad overlap in cardiovascular, peripheral, and endoscopy devices
- Teleflex
Direct vascular access and interventional-device overlap
- BD
Peripheral intervention, biopsy, drainage, and access overlap
- Medtronic
Large-scale overlap in cardiac, vascular, spine, and endoscopy
- Abbott
Cardiac intervention overlap in EP, rhythm, and vascular devices
- Edwards Lifesciences
Named cardiac-intervention peer in structural heart procedures
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Merit Medical Systems | $87.30 | +0.05% | $5.21B | 36.1 | 20.0 | 3.3 | +9.5% |
| Boston Scientific | $44.75 | −0.38% | $66.77B | 18.3 | 13.6 | 3.2 | +7.5% |
| Teleflex | $123.74 | −0.93% | $5.53B | — | 13.4 | 2.1 | −27.0% |
| BD | $183.19 | +0.10% | $50.42B | 55.1 | 13.8 | 2.4 | −9.6% |
| Medtronic | $90.08 | −0.77% | $116.19B | 22.4 | 15.0 | 3.1 | +13.7% |
| Abbott | $104.08 | +0.34% | $179.49B | 33.4 | 18.0 | 3.9 | +13.0% |
| Edwards Lifesciences | $87.88 | −1.01% | $51.12B | 51.0 | 28.0 | 7.8 | +13.6% |
| Median | 33.4 | 14.4 | 3.1 | +10.3% |